Literature DB >> 32938723

LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial.

Annette Hasenburg1, Jalid Sehouli2, Bjoern Lampe3, Alexander Reuss4, Barbara Schmalfeld5,6, Antje Kristina Belau7, Michaela Bossart8, Sven Mahner6,9, Peter Hillemanns10, Ulrich Petry11, Andreas du Bois12, Uwe Herwig13, Felix Hilpert14,15, Martina Gropp-Meier16, Volker Hanf17, Elfriede Greimel18, Uwe Wagner19, Philipp Harter12.   

Abstract

BACKGROUND: There is limited information about the impact of radical surgery including pelvic and para-aortic lymphadenectomy and subsequent platinum-based chemotherapy on sexuality in patients with advanced ovarian cancer.
OBJECTIVE: To evaluate the impact of radical surgery including pelvic and para-aortic lymphadenectomy and subsequent platinum-based chemotherapy on sexuality in patients with advanced ovarian cancer as a sub-protocol of the prospectively randomized LION trial.
METHODS: The Sexual Activity Questionnaire was applied to assess sexual function according to its sub-scales activity, pleasure, and discomfort. The 'orgasm' sub-scale from the Female Sexual Function Index was also added. The questionnaire was administered in combination with the EORTC QLQ-C30 questionnaire at baseline prior surgery, after 6, 12, and 24 months. The primary endpoint was changes in sexual function.
RESULTS: Overall, 495 patients received the questionnaires. 254 (51%) responded at baseline. Of these, 55 (22%) patients were sexually active, 182 (72%) were sexually inactive, and for 17 (7%) patients' data were not available. There was a total of 55/495 (11%) patients at 6 months, 139 (28%) patients at 12 months, and 81 (16%) patients at 24 months. Median age was 60.5 years (range 21.4-75.8). At baseline, sexually active responders were significantly younger (median age 51.5 years,) than sexually inactive responders (median age 61.8 years) and tended to have a better performance status. Discomfort evaluated as dryness of the vagina and pain during sexual intercourse was significantly worse at 12 months than at baseline (p<0.001); however, the surgical variable, lymphadenectomy, did not have any impact on this. The orgasm sub-scale showed diverging results with a deterioration from baseline to 12 months in the lymphadenectomy group compared with the no-lymphadenectomy group (p=0.02).
CONCLUSION: The majority of patients were sexually inactive; however, in those who were sexually active, pain during intercourse was worse at 12 months. In addition, the orgasm sub-scale demonstrated worse results in patients who underwent complete lymphadenectomy. The study suggests that surgery in the retroperitoneal space may influence sexual function. © IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  SLN and lympadenectomy; gynecologic surgical procedures; ovarian cancer; quality of life (PRO)/palliative care

Year:  2020        PMID: 32938723     DOI: 10.1136/ijgc-2020-001551

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  2 in total

1.  Nerve-Sparing Systematic Lymph Node Dissection in Gynaecological Oncology: An Innovative Neuro-Anatomical and Surgical Protocol for Enhanced Functional Outcomes.

Authors:  Mustafa Zelal Muallem; Yasser Diab; Thomas Jöns; Jalid Sehouli; Jumana Muallem
Journal:  Cancers (Basel)       Date:  2020-11-22       Impact factor: 6.639

2.  The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group.

Authors:  Annette Hasenburg; Hellmut Plett; Bernhard Krämer; Elena Braicu; Bastian Czogalla; Michaela Bossart; Susanne Singer; Doris Mayr; Annette Staebler; Andreas du Bois; Stefan Kommoss; Theresa Link; Alexander Burges; Florian Heitz; Jacqueline Keul; Fabian Trillsch; Philipp Harter; Pauline Wimberger; Paul Buderath; Maximilian Klar
Journal:  Arch Gynecol Obstet       Date:  2021-07-21       Impact factor: 2.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.